Identity recordFDA-approved US medicine with country-specific status elsewhere
What Orforglipron / Foundayo resolves to
FOUNDAYO is an FDA-approved US oral medicine containing the non-peptide small molecule orforglipron. That US approval does not establish authorization, launch, prescription access, market presence, supply, or seller authority in another country, and it does not authenticate a same-name research or imported product.
- Evidence lane
- FDA-approved medicine
- Current record
- NDA 220934 · FDA-approved prescription drug
- Checked
- July 20, 2026
orforglipronFoundayoLY3502970NDA 220934oral GLP-1
Destination recordHSA product and e-pharmacy checks
What Singapore still has to prove
A Singapore guide to checking peptide-related offers through HSA's therapeutic-product register, licensed dealer and retail-pharmacy searches, and e-pharmacy requirements.
- Comparison mode
- SGD / HSA product, dealer, and pharmacy records
- Price coverage
- No qualified Singapore seller table
- Guide updated
- July 18, 2026